Characterization of Anti-Insulin Antibodies in Type 1 and Type 2 Diabetes Mellitus: Clinical Relevance
International Journal of Molecular Sciences · 18.02.2025 · 26 (4) · 1730
DOI: 10.3390/ijms26041730 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 18.02.2025. Verfasst von Henrik Toft-Hansen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Non-Clinical and Clinical Assay Sciences, Novo Nordisk A/S, DK-2760 Maaloev, Denmark. Hauptthemen laut MEDLINE: Insulin Antibodies, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovation Fund Denmark, Novo Nordisk.
Themen: Diabetes mellitus
Abstract (Originalsprache)
The administration of insulin as a treatment for diabetes frequently leads to the formation of anti-insulin antibodies (IAs). The influence of these antibodies on the efficacy and safety of insulin therapy remains incompletely understood. This study presents a systematic, exploratory, cross-sectional analysis of the quantitative and qualitative properties of IAs in 101 patients with type 1 diabetes (T1D) and 101 patients with type 2 diabetes (T2D). The goal was to identify subpopulations of IAs that might impact glycemic control. We assessed the presence, titer, isotype, subclass, avidity, and in vitro neutralizing capacities of IAs, using glycated hemoglobin A1c (HbA1c) levels as an indicator of the clinical effectiveness of insulin. Our findings showed that 72% of individuals with T1D and 32% with T2D developed IAs, with IgG being the predominant isotype in both groups. Despite the presence of IAs, no in vitro neutralizing effect against insulin was observed, and there was no significant correlation between IA titer or avidity and HbA1c levels in either group. The results from this study demonstrate that while IAs are prevalent in both T1D and T2D, they do not have a significant clinical impact on the outcomes of insulin therapy in our study populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Non-Clinical and Clinical Assay Sciences, Novo Nordisk A/S, DK-2760 Maaloev, Denmark.
- Centre for Functional Assays and Screening, Novo Nordisk A/S, DK-2760 Maaloev, Denmark.
- Steno Diabetes Center Copenhagen, DK-2730 Herlev, Denmark.
- Department of Clinical Medicine, University of Copenhagen, DK-2200 Copenhagen, Denmark.
- Pacific Northwest Research Institute, Seattle, WA 98122, USA.
- Institute for Inflammation Research, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, DK-2100 Copenhagen, Denmark.
ORCID-Profile: Daniel Elias, William A Hagopian, Darius A Schneider
Förderung
- Innovation Fund Denmark
- Novo Nordisk
Zitieren
APA
Toft-Hansen, H., Aniol-Nielsen, C., Elias, D., Dahlbäck, M., Rossing, P., Sivalingam, S., Hagopian, W. A., Schneider, D. A., Nielsen, C. H., & Solberg, H. (2025). Characterization of Anti-Insulin Antibodies in Type 1 and Type 2 Diabetes Mellitus: Clinical Relevance. International Journal of Molecular Sciences, 26(4), 1730. https://doi.org/10.3390/ijms26041730
Vancouver
Toft-Hansen H, Aniol-Nielsen C, Elias D, Dahlbäck M, Rossing P, Sivalingam S, et al. Characterization of Anti-Insulin Antibodies in Type 1 and Type 2 Diabetes Mellitus: Clinical Relevance. International Journal of Molecular Sciences. 2025;26(4):1730. doi:10.3390/ijms26041730
BibTeX
@article{ToftHansen2025,
author = {Toft-Hansen, Henrik and Aniol-Nielsen, Christina and Elias, Daniel and Dahlbäck, Madeleine and Rossing, Peter and Sivalingam, Suvanjaa and Hagopian, William A and Schneider, Darius A and Nielsen, Claus H and Solberg, Helene},
title = {Characterization of Anti-Insulin Antibodies in Type 1 and Type 2 Diabetes Mellitus: Clinical Relevance},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {4},
pages = {1730},
doi = {10.3390/ijms26041730}
}
EUVIMED